Globus Medical has delivered a strong 77.0% share price gain over the past three years, which puts fresh focus on a simple question for anyone looking at the stock today. Is the current US$80.90 price properly supported by the earnings the business is generating right now?
- The 77.0% return over three years puts long term holders in a comfortable position. This raises the stakes for whether the current earnings justify locking in at this valuation level.
- The rollout of SCRIPT patient specific spinal implants and the XLIF Prone solution may support expectations for future procedure volumes and pricing power. This can feed into how much investors are willing to pay for Globus Medical's earnings stream.
- The analysts covering Globus Medical have run their own numbers. See what analysts think Globus Medical's shares could be worth.
The issue now is whether the earnings that Globus Medical produces today are strong enough to make the current share price look sensible on an earnings based yardstick.
If you are weighing Globus Medical against other earnings focused ideas in healthcare, it can help to compare it with a broader set of 34 healthcare AI stocks.
Is Globus Medical Still Cheap on Earnings?
A P/E lens suits Globus Medical because earnings are a core focus for how investors currently frame this business. On that measure, the stock trades on roughly 20.3x earnings, which is below the Medical Equipment sector average of about 26.9x and well under the peer group near 39.4x.
Because the stock commands a lower P/E than the tailored fair multiple implied by its own profile, the shares screen as undervalued on this yardstick. Despite the recent law firm probe into potential fiduciary breaches keeping some scrutiny on governance, the current P/E still places Globus Medical at a discount to where a more customised model would place it. Explore the numbers behind Globus Medical's P/E valuation.
The Globus Medical Narrative: What Would Justify Today's Price?
Globus Medical's valuation raises a simple follow up question that Narratives aim to answer. They explain which paths for Globus Medical's future growth, margins and earnings would need to occur for the shares to trade meaningfully higher or lower than today. Where a single ratio or model gives one figure, they turn that number into a specific future to watch on Simply Wall St's Community page so you can track whether it plays out.
One of the top community narratives on Globus Medical: 20% undervalued
"Disciplined capital allocation, including use of roughly half of free cash flow for share repurchases, a debt free balance sheet with US$840.5 million of cash and securities…"
Discover why this Narrative puts Globus Medical at 20% undervalued.
Globus Medical’s leaders could tilt the risk and reward
Before you lean too hard on the numbers alone, it is worth checking who is steering Globus Medical and how their pay packets line up with your interests as a shareholder. See who runs Globus Medical and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com